Novartis Benefits From Lack of Generic Challenge

Novartis Benefits From Lack of Generic Challenge Play

April 24 (Bloomberg) -- Bloomberg's Jonathan Ferro reports that Novartis AG saw first-quarter profit rise 7 percent as a competitor's generic version of the company’s second-best-selling medicine failed to reach the market. He speaks on Bloomberg Television's "On The Move."

Feed Most Popular

  • On Air Now

    Studio 1.0: Scooter Braun Watch Now

  • Next

    Studio 1.0: Marc Andreessen

blog comments powered by Disqus